Researchers at the University of Illinois Chicago have unlocked a promising new avenue in the fight against cancer by harnessing compounds from bacteria residing within breast tumors. This innovative approach centers on a synthetic peptide named aurB, derived from a protein called auracyanin found in photosynthetic bacteria identified in patient tumor samples. The discovery highlights the untapped potential of the tumor microbiome—the community of microbes living alongside cancer cells—and positions UIC at the forefront of translating microbial insights into targeted therapies.
The work, led by Tohru Yamada, an associate professor in the departments of surgery and biomedical engineering, builds on years of studying bacteria-cancer interactions. In a recent preclinical study, aurB demonstrated remarkable efficacy, particularly when combined with radiation, effectively halting tumor growth in models of advanced prostate cancer. This development not only offers hope for treatment-resistant cases but also underscores how university-led research is reshaping oncology.
🌱 Exploring the Tumor Microbiome: A Hidden World Inside Cancer
The concept of bacteria living within tumors may sound surprising, but scientists have known for decades that the tumor microenvironment—a complex ecosystem of cells, blood vessels, and microbes—plays a crucial role in cancer progression. Mitochondria-Targeting Peptide from Tumor Bacteria at UIC Recent advances in DNA sequencing have revealed diverse bacterial communities in various cancers, including breast tumors.
At UIC, researchers analyzed tumor samples from breast cancer patients using 16S rRNA gene sequencing, a technique that identifies bacterial DNA. They pinpointed bacteria from the Chloroflexia phylum, particularly those carrying the auracyanin gene. Auracyanin is a cupredoxin, a family of copper-containing proteins that facilitate electron transfer in bacteria. These proteins caught attention because previous UIC work on similar bacterial redox proteins, like azurin from Pseudomonas aeruginosa, showed potent anti-tumor effects.
This microbiome research reflects a shift in oncology: from viewing bacteria solely as pathogens to recognizing them as potential allies. In breast tumors, these microbes may influence inflammation, immune responses, and even drug resistance, providing a rich source for novel compounds.
From Bacterial Protein to Therapeutic Peptide: UIC's Design Process
Tohru Yamada's team at UIC meticulously engineered aurB by selecting residues 61–88 from auracyanin B, creating a 28-amino-acid peptide that is anionic and amphipathic—properties allowing it to penetrate cancer cells effectively. Synthesized to high purity, aurB was rigorously tested in lab settings.
The design drew from evolutionary biology: chloroplasts in plants, which evolved from ancient bacteria, share proteins with mitochondria, the cell's energy hubs. Cancer cells, with their hyperactive mitochondria, rely heavily on ATP production for rapid division, making this an ideal vulnerability.
Unlike earlier peptides dependent on the p53 tumor suppressor gene—mutated in over half of cancers—aurB operates independently, broadening its applicability. This step-by-step engineering exemplifies how UIC's interdisciplinary teams blend microbiology, bioengineering, and oncology.
- DNA sequencing of breast tumor samples to identify target bacteria
- Structural analysis of auracyanin for peptide mimicry
- Synthesis and purification of aurB
- In vitro testing on cancer cell lines
The Mechanism: Starving Cancer Cells of Energy
AurB's power lies in its precision strike on mitochondria. Upon entering tumor cells, it localizes to these organelles, binding tightly to ATP5C, a subunit of ATP synthase—the enzyme powering ATP synthesis. This blockade disrupts oxidative phosphorylation and glycolysis, slashing cellular energy levels.
Experiments using confocal microscopy, flow cytometry, and transmission electron microscopy confirmed aurB's mitochondrial targeting, showing swelling, membrane potential loss, and halted respiration. In p53-inactive prostate cancer cells like DU145 and PC3, aurB triggered caspase-3-mediated apoptosis, reducing viability by about 50% at therapeutic doses while sparing normal cells.
This energy deprivation mimics starvation, forcing cancer cells into programmed death without the broad toxicity of chemotherapy. For patients with mutated p53, common in advanced breast and prostate cancers, this represents a game-changer.
Preclinical Triumphs: Shutting Down Tumor Growth
In mouse models, aurB shone brightly. Subcutaneous PC3 xenografts treated with intraperitoneal aurB (5 mg/kg) saw tumors shrink by 65%, outperforming controls, prior peptide p28, and paclitaxel. Proliferation marker Ki-67 dropped, while apoptosis surged.
The real breakthrough came in a tibial bone metastasis model using DU145-luc cells, mimicking late-stage prostate cancer spread. AurB alone curbed growth by 68% and lung metastases by 21%. No systemic toxicity emerged, a critical safety signal.
Multiplex RNA profiling revealed aurB upregulated pathways enhancing cell death and curbed survival signals, positioning it as a versatile agent.
Radiation Synergy: A Powerful Combination Therapy
Radiation therapy remains a cornerstone for many cancers, including prostate, but resistance limits its success. AurB amplified radiation's punch: in the bone metastasis model, the duo slashed tumor growth by 99% and lung lesions by 91%.
RNA analysis pinpointed HIF-1α modulation— a hypoxia-inducible factor driving radioresistance. AurB downregulated PI3K and GLUT-1 pathways, sensitizing tumors. This synergy could revive radiation for resistant cases, reducing doses and side effects.
UIC's findings suggest broader combos with chemo or immunotherapy, leveraging the tumor microenvironment.
Overcoming Limitations of Current Cancer Therapies
Traditional treatments like chemotherapy ravage healthy cells, while targeted drugs falter against mutations like p53 loss. AurB sidesteps these: p53-independent, mitochondria-focused, and bacteria-inspired for novelty.
In hormone-resistant prostate cancer, where options dwindle, aurB offers precision. For breast cancer, from whose tumors it originated, it holds promise amid rising microbiome-aware strategies. US stats underscore urgency: over 290,000 new breast cancers yearly, 2.3 million prostate cases globally, many metastatic.
- p53-independent action broadens patient eligibility
- Mitochondrial targeting exploits cancer's energy addiction
- Low toxicity profile improves quality of life
- Synergy boosts existing standards like radiation
Broad Potential: From Prostate to Breast and Beyond
Though tested in prostate models, aurB's origins in breast tumors suggest direct relevance. Breast cancer cells like MCF-7 showed sensitivity in vitro. Its mechanism suits aggressive, metabolically active tumors across types.
UIC's prior azurin work reached clinical trials for brain cancers, paving aurB's path. Patented via UIC's Office of Technology Management, it's primed for industry partnerships.
UIC Cancer Center: Driving Translational Research
The University of Illinois Cancer Center, where Yamada serves, fosters such breakthroughs through multidisciplinary collaboration. Partners from surgery, engineering, and pathology accelerated aurB from bench to preclinical proof.
UIC's tumor microbiome expertise stems from Yamada's lab, credited by the Department of Surgery. This ecosystem translates discoveries into therapies, training next-gen researchers via PhD programs and fellowships.
Path Forward: Clinical Trials and Global Impact
With patent secured, UIC eyes human trials, potentially via FDA IND. Challenges include scaling synthesis and optimizing dosing, but preclinical safety bodes well.
Broader implications: revitalizing antibiotic-era ideas for oncology, inspiring microbiome mining worldwide. For US higher ed, it spotlights public universities' role in health innovation amid NIH funding cuts.
Career Opportunities in Cancer Microbiome Research
This UIC milestone opens doors for bioengineers, microbiologists, and oncologists. Roles in peptide design, preclinical modeling, and trials abound at research universities. Skills in sequencing, CRISPR, and animal models are prized.
Grad students can pursue UIC's biomedical engineering PhD, blending bacteria with cancer tech. Postdocs find fellowships via NIH, while faculty track emphasizes translational impact.
